SCHEMBL285785

SCHEMBL285785

Cc1ccc(CCCCO)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.59
ALOX15 P16050 1/20 0.59
CYP4A11 Q02928 2/20 0.53
CYP4F2 P78329 1/20 0.53
CA2 P00918 3/20 0.52
CYP1A2 P05177 1/20 0.50
CYP2A6 P11509 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
HRH1 P35367 1/20 0.48
GAA P10253 1/20 0.45
ESR1 P03372 2/20 0.43
ADRA2A P08913 2/20 0.43
ADORA3 P0DMS8 2/20 0.43
TACR2 P21452 2/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6207049 0.98 IGF1R (0.57) IGF1RALOX15CYP4A11CYP4F2CA2
SCHEMBL93545 0.98 IGF1R (0.57) IGF1RALOX15CYP4A11CYP4F2CA2
SCHEMBL12827576 0.98 IGF1R (0.57) IGF1RALOX15CYP4A11CYP4F2CA2
SCHEMBL11286656 0.98 IGF1R (0.57) IGF1RALOX15CYP4A11CYP4F2CA2
SCHEMBL9422698 0.98 IGF1R (0.57) IGF1RALOX15CYP4A11CYP4F2CA2
P-Xylene SCHEMBL6429103 0.98 IGF1R (0.57) IGF1RALOX15CYP4A11CYP4F2CA2
Methyl Alcohol SCHEMBL9951500 0.96 IGF1R (0.55) IGF1RALOX15CYP4A11CYP4F2CA2
SCHEMBL80441 0.93 IGF1R (0.55) IGF1RALOX15CYP4A11CYP4F2CA2
Toluene SCHEMBL7575476 0.92 IGF1R (0.52) IGF1RALOX15CYP4A11CYP4F2CA2
SCHEMBL6546754 0.87 IGF1R (0.64) IGF1RALOX15CYP1A2CYP2A6TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275917-A1 TOPICAL FOAMABLE PHARMACEUTICAL COMPOSITION EUROFARMA LABORATORIOS S.A. (BR) 2025-09-04 US claimed
CN-113049685-B Quality detection method of compound radix zanthoxyli lozenge 广西壮族自治区花红药业股份有限公司 2024-07-30 CN claimed
EP-4282418-A9 FOAMING TOPICAL PHARMACEUTICAL COMPOSITION Eurofarma Laboratórios S.A. (BR) 2024-07-17 EP claimed
EP-4282418-A1 FOAMING TOPICAL PHARMACEUTICAL COMPOSITION Eurofarma Laboratórios S.A. (BR) 2023-11-29 EP claimed
CN-116283726-A Preparation method and application of cyanine dye variant and cyanine protein composite fluorophore 吉林大学第一医院 2023-06-23 CN claimed
CN-113248940-B Heptamethine cyanine dye with high-selectivity red light absorption, and synthesis method and application thereof 上海戎科特种装备有限公司 2023-02-17 CN claimed
WO-2022178604-A1 FOAMING TOPICAL PHARMACEUTICAL COMPOSITION EUROFARMA LABORATORIOS S.A. (BR) 2022-09-01 WO claimed
CN-113683602-B Heptamethine cyanine micromolecule for multi-modal treatment of hypoxic tumors, and preparation method and application thereof 中国人民解放军陆军军医大学 2022-06-10 CN claimed
CN-113683602-A Heptamethine cyanine small molecule for multi-modal treatment of hypoxic tumors, and preparation method and application thereof 中国人民解放军陆军军医大学 2021-11-23 CN claimed
CN-108084325-B Preparation of acrylic resin and application of acrylic resin in antifouling paint 浙江海洋大学 2021-03-30 CN claimed
US-20060083706-A1 Haircare composition comprising at least one electrophilic monomer and micro- or nanoparticles of at least one solid lubricant L'OREAL S.A. (FR) 2006-04-20 US claimed
US-20060078523-A1 Composition comprising at least one electrophilic monomer and at least one acid in a cosmetically acceptable anhydrous medium, and use thereof for cosmetic treatment of the hair L'OREAL S.A. (FR) 2006-04-13 US claimed
US-20060078522-A1 Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt L'OREAL S.A. (FR) 2006-04-13 US claimed
US-20030175229-A1 Electrophilic monomers for treating the hair L'OREAL (FR) 2003-09-18 US claimed
US-5700468-A CONSISTS OF GINKGO FLAVONE GLUCOSIDES, PROANTHOCYANIDINES, GINKGOLIDES, BILOBALIDE, AND SULFURIC ASH; FREE OF ALKYL PHENOL; USEFUL FOR TREATING VASCULAR SYSTEM DISORDER INDENA SPA (IT) 1997-12-23 US claimed
US-5637302-A SOLVENT EXTRACTION FROM LEAVES INDENA SPA (IT) 1997-06-10 US claimed
EP-0360556-B1 NEW EXTRACTS OF GINKGO BILOBA AND THEIR METHODS OF PREPARATION INDENA S.p.A. (IT) 1993-04-21 EP claimed
EP-0360556-A1 New extracts of ginkgo biloba and their methods of preparation INDENA S.p.A. (IT) 1990-03-28 EP claimed
EP-0225785-A2 Preparation of mono-disperse metal oxides AKZO N.V. (NL) 1987-06-16 EP claimed
US-4204987-A Aqueous polyester dispersion for adhering vinyl film to wood THE GOODYEAR TIRE & RUBBER COMPANY (US) 1980-05-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030175229-A1 Electrophilic monomers for treating the hair NACA, SUCLG1, TYR IGF1R 4818/4885ALOX15 677/4885CYP4A11 2989/4885
US-20060083706-A1 Haircare composition comprising at least one electrophilic monomer and micro- or nanoparticles of at least one solid lubricant MITF, CUTA, NACA IGF1R 3089/4885ALOX15 3511/4885CYP4A11 4744/4885
US-20060078523-A1 Composition comprising at least one electrophilic monomer and at least one acid in a cosmetically acceptable anhydrous medium, and use thereof for cosmetic treatment of the hair HOGA1, OAT, SUCLG1 IGF1R 4356/4885ALOX15 467/4885CYP4A11 3077/4885
US-20060078522-A1 Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt KRT18, DSG1, DSC1 IGF1R 4451/4885ALOX15 3822/4885CYP4A11 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.